Daclatasvir/sofosbuvir and ribavirin 800 mg flat dose is highly efficacy and safe in genotype 3 compensated and decompensated cirrhotic patients: The CLEO experience. Issue 1 (16th February 2017)

• Record Type: Journal Article
• Authors: Pellicelli, A.; Messina, V.; Tarquini, P.; Pace Palitti, V.; Ceccherini Silberstein, F.; Pompili, M.; Gulminetti, R.; Cerasari, G.; D'Ambrosio, C.; Villani, R.; Fondacaro, L.; Dell'isola, S.; Babudieri, S.; Iovinella, V.; Di Candilo, F.; Chiesara, F.; Di Maio, V.C.; Ponziani, F.R.; Sacco, R.; Izzi, A.; Moretti, A.; Giannelli, V.; Perno, C.F.; Barbarini, G.
• Is Part Of: Digestive and liver disease. Volume 49:Issue 1(2017)Supplement
• Page Start: e64
• Publication Date: 2017-02-16
• Subjects: Digestive organs -- Diseases -- Periodicals; Liver -- Diseases -- Periodicals; 616.33005
• DOI: 10.1016/j.dld.2017.01.127
• Languages: English
• ISSNs: 1590-8658